Welcome!

Premium Services
- My Services
- None
- Other Services
- Champion Funds
- Duke Street
- Global Gains
- Hidden Gems
- Income Investor
- Inside Value
- Million Dollar Portfolio
- Motley Fool Options
- Motley Fool Pro
- Pay Dirt
- Ready-Made Millionaire
- Rule Breakers
- Rule Your Retirement
- Stock Advisor
- *Get a Fool Credit Card

Help Join Now or

Updated: 11/9/2009 4:03 PM					Sponsored by:
	DOW	10226.94	203.52	2.03%
	S&P 500	1093.08	23.78	2.22%
	NASD	2154.06	41.62	1.97%

Exact Sciences rejects Sequenom acquisition offer

By Associated Press
January 12, 2009 | Comments (0)

Recs

0

Cancer test maker Exact Sciences Corp. said Monday its board unanimously rejected an acquisition offer by Sequenom Inc.

Genetic analysis product maker Sequenom said Friday it had offered to buy Exact Sciences for $41 million. San Diego-based Sequenom said it believed Exact Sciences' cancer tests fit well with Sequenom's MassArray genetic research systems and other DNA tests.

Exact Sciences said in a brief statement it was pursuing a "strategic alternative" that its board believes will offer greater value to shareholders than the Sequenom deal. The statement did not elaborate.

The Sequenom deal valued Exact Sciences shares at $1.50.

Exact Sciences shares rose more than 50 percent, or 51 cents, to $1.50 in trading Monday, while Sequenom stock fell 3 percent, or 73 cents, to $22.29.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

DocumentId: 808564, ~/Articles/ArticleHandler.aspx, 11/9/2009 8:56:14 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.